Special Issue Announcement: Therapy and prognosis of metastatic prostate cancer
Special Issue Title: Therapy and prognosis of metastatic prostate cancer Download Flyer
Deadline for manuscript submissions: 31 August 2021
Please let me invite you to contribute to the preparation and later to favour a mindful lecture of this speciel issue of the Journal of Men’s Health dedicated to metastatic prostate cancer.
Although being a leading cause of cancer death, metastatic prostate cancer, compared to other cancer types, is any longer necesserily a life threatening condition. Thanks to recent pharmaceutical developments, several lines of anti-hormonal and cytostatic treatments may provide long years of disease control.
We would like to focus in this special issue to the diagnostic challenges, to the proper use of innovative therapies and to the patients’ perspectives open with the improved prognosis. Differentiating between localised and generalised disease remains problematic even with the best imaging techniques. Sequencing and maintenance of novel drugs are being debated. The men’s own evaluation of the quality of their prolonged life is maybe not enough taken into account.
This special issue offers an opportunity to address the following but other topics:
- Diagnosis and treatment of oligometastatic disease
- Diagnosis and treatment of micrometastatic disease
- Diagnosis and treatment of neuroendocrin cancer of the prostate
- Optimal selection of systemic therapies
- Optimal maintenance of second line antiandrogenic therapies
- Optimal comedication of androgen synthesis inhibitors
- Optimal dosing of bisphosphonates
- Quality of life of patients with metastatic prostate cancer
As many questions that can not be answered by referring exclusively on clinical trials, allowing therefore a considerable role to journals with smaller impact like the Journal of Men’s Health. Your contribution is welcome in form of original article, case report, commentary and review.
Let’s share our experience to the better care of the patients of all of us.
Dr. Kullmann Tamás, PhD, Department of Oncology, Petz Aladár Hospital, Győr, Hungary
Research interest: Infections and malignancies of the urinary tract, Diagnosis of “fever of unknown origin”, Oncologic emergencies, Pain relief for cancer patients
Manuscript Submission Information:
Manuscripts should be submitted online at www.jomh.org by registering and logging in to journals website. Once you are registered, go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a double-blind peer-review process. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office (firstname.lastname@example.org).
A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page of the journal. Submitted papers should be well formatted and use good English.
The Article Processing Charge (APC) for publication in this open access journal is $1100. We normally offer a 30% discount to all contributors invited by the Editor-in-Chief, Guest Editor (GE) and Editorial Board Member.
Type of Articles: Review, Mini-Review, Systematic Review, Short Communication, Case Report, Letter to the Editor, Commentary, Rapid Report, Meeting Report, News and Views